Keith Sarbaugh
EVP & Chief Digital & Technology Officer
Zoetis
Keith Sarbaugh is Executive Vice President and Chief Digital and Technology Officer at Zoetis, the world’s leading animal health company and a member of the Fortune 500.
In this role, Mr. Sarbaugh is responsible for the company’s technology, AI and digital, and cybersecurity strategy, while also overseeing the global customer experience function.
Mr. Sarbaugh joined Zoetis in March 2023 as Vice President and Chief Information Officer, where he led the business partnering teams, enterprise applications, infrastructure, and operations.
Prior to joining Zoetis, Mr. Sarbaugh was Vice President, Information Technology at Biogen, where he oversaw global infrastructure, IT operations, and enterprise architecture. With nearly 25 years of experience in technology, digital and data, he has held various leadership roles at Eli Lilly and Company, including Head of IT Infrastructure and Enabling Functions and Regional Chief Information Officer for Lilly’s U.S. Commercial, Southeastern and Central Eastern European businesses.
Dedicated to advancing enterprise value, Mr. Sarbaugh drives innovation through strategic digital and AI initiatives, advocating for bold, calculated investments that deliver measurable business outcomes. He is deeply committed to developing early career talent, actively championing and sponsoring internship programs that equip students with invaluable, real-world experience and lay a strong foundation for their professional journeys. Recognizing the need to nurture future leaders, he partners with educational institutions to bridge the gap between academic learning and industry practice, engaging directly with aspiring talent. Beyond early career development, Mr. Sarbaugh actively supports technology professionals at every stage, fostering continuous growth and building a robust leadership pipeline to ensure the organization’s long-term success.
Jeanne Riot
Associate Director Sustainable Supply Chain
KPMG
Ben Olson
Chief Medical Officer
COVE Animal Health
Andrew Kopsidas
Partner
Blank Rome
Paul Zeineddin
Partner
Blank Rome
Jim Harrington
Chief Intellectual Property Counsel
Vera Therapeutics
Chuck Klein
Partner
Winston Taylor
With US courts continuing to refine the scope of § 271(e)(1) and the European Pharma Package proposing to extend and reshape Bolar exemptions across member states, this session examines the latest litigation and regulatory developments shaping how life sciences companies structure pre-approval activity on both sides of the Atlantic.
- Examine where the line is currently being drawn under § 271(e)(1), and what recent decisions including Jazz v. Avadel (Fed. Cir. May 2025) and Ascendis v. BioMarin (ITC, ongoing), tell us about the boundaries of protected pre-approval activity.
- How to structure pre-approval activity to make the most of safe harbor protection, and where its limitations continue to drive disputes.
- Discuss the European Pharma Package's proposed extension and reshaping of Bolar exemption means for originator and generic strategy, and how US companies are adapting their pre-approval strategies in response.
Aaron Clay
Director - Intellectual Property Litigation
Merck
Chuck Sholtz
Head of IP
Verdiva Bio
Sophie Wang
Co-Head - IP Litigation
Choate
Sophie Wang is a Partner in Litigation and is Co-Head of the IP Litigation practice. She is a first-chair trial lawyer who represents biotech, pharmaceutical, and technology companies in complex and high stakes intellectual property and commercial disputes across the country. Sophie is a go-to resource for clients in the life sciences industry, including for “bet-the-company” patent litigation (including Hatch-Waxman and biosimilar litigation), post-grant review (PGR) and inter partes review (IPR) proceedings before the United States Patent Trial and Appeal Board (PTAB), trade secrets litigation, and contract, licensing, and other commercial disputes. She also routinely advises clients on the management of their US and global patent and litigation strategies, including regularly consulting with counsel before the EPO and in the UK, Germany, and other foreign jurisdictions.
Dr. Sarah Salaschek
Attorney at Law and Patent Litigator
Bonabry
Dr. Sarah Salaschek is attorney at law and patent litigator, working in the Hamburg office of Bonabry. She mainly advises clients in the pharmaceutical industry and represents them before German courts as well as before the Unified Patent Court. Her practice covers all questions of intellectual property law with a particular focus on pharma patents, SPCs and related regulatory issues.